Hidaka Y
Teikyo University School of Medicine, Third Department of Internal Medicine.
Nihon Rinsho. 1996 Dec;54(12):3374-8.
Anderson proposed three genetic diseases deficient in enzymes involved in purine metabolism as candidate for human gene therapy in 1984. Over the past ten years, marked advances in molecular genetics have brought gene therapy to reality. Gene therapy for ADA deficiency was performedin the United States in 1990 and in Japan in 1995 as the first trial. Basic study for HPRT gene transfer has been proceeding toward gene therapy for HPRT deficiency despite the difficulties in gene transfer into the nervous systems.
1984年,安德森提出三种参与嘌呤代谢的酶缺乏的遗传性疾病作为人类基因治疗的候选对象。在过去十年中,分子遗传学取得了显著进展,使基因治疗成为现实。1990年在美国和1995年在日本进行了腺苷脱氨酶缺乏症的基因治疗作为首例试验。尽管向神经系统进行基因转移存在困难,但次黄嘌呤鸟嘌呤磷酸核糖转移酶基因转移的基础研究一直在朝着次黄嘌呤鸟嘌呤磷酸核糖转移酶缺乏症的基因治疗方向推进。